Driving Efficiency: Leveraging Model-Informed Approaches in 505(b)(2) Regulatory Actions

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science
• Drug Development

Background:

• The Hatch-Waxman Amendments of 1984 established the 505(b)(2) application pathway.
• This pathway allows the FDA to approve new drugs by referencing previous studies, avoiding duplicative testing.
• It offers a more efficient and expedited route for drug approval compared to traditional methods.

Purpose of the Study:

• To discuss the application of model-informed drug development (MIDD) within the 505(b)(2) regulatory framework.
• To highlight how quantitative models can enhance the efficiency and effectiveness of 505(b)(2) submissions.
• To demonstrate the value of MIDD in supporting regulatory decisions for new drug applications.

Main Methods:

• Review of case studies where MIDD approaches were applied to support 505(b)(2) submissions.
• Utilization of quantitative models, including population pharmacokinetic and exposure-response models.
• Integration of physiological, disease, and pharmacological knowledge into modeling.

Main Results:

• MIDD approaches provided evidence of effectiveness for 505(b)(2) applications.
• Models guided dosing recommendations for specific patient subgroups, such as those with hepatic or renal impairment.
• Quantitative modeling informed regulatory policies and decision-making processes.

Conclusions:

• Model-informed drug development significantly contributes to expediting the approval of new drugs via the 505(b)(2) pathway.
• The strategic use of quantitative models strengthens evidence for effectiveness and supports regulatory actions.
• MIDD is a valuable tool for optimizing drug development and regulatory decision-making in the context of 505(b)(2) submissions.